Robyn M Scherber1,2, Heidi E Kosiorek3, Zhenya Senyak4, Amylou C Dueck3, Matthew M Clark5, Michael A Boxer6, Holly L Geyer1, Archie McCallister4, Mary Cotter4, Barbara Van Husen7, Claire N Harrison8,9, Ruben A Mesa1. 1. Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona. 2. Department of Hematology and Oncology, Oregon Health and Science University, Portland, Oregon. 3. Division of Biostatistics, Mayo Clinic, Scottsdale, Arizona. 4. MPN Forum, MPN Research Foundation, Chicago, Illinois. 5. Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota. 6. Arizona Oncology, Tucson, Arizona. 7. MPN Research Foundation, Chicago, Illinois. 8. Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom. 9. MPN Voice, London, United Kingdom.
Abstract
BACKGROUND: Patients with myeloproliferative neoplasms (MPNs) experience a high persistence, prevalence, and severity of fatigue. There is currently only limited information regarding factors that contribute to fatigue in patients with MPNs. METHODS: A 70-item, Internet-based survey regarding fatigue was developed by MPN investigators and patients/advocates and hosted by the Mayo Clinic Survey Research Center. RESULTS: Fatigue was found to be prevalent and severe among international survey respondents (1788 respondents). Higher body mass index (P<.001), current use of alcohol (P<.001), and current tobacco use (P = .0025) were found to be significantly associated with greater fatigue. Moderate/severe fatigue was present more frequently in those individuals who did not exercise compared with those who reported exercising at least once per week (P<.001). Medical comorbidities found to be significantly associated with greater fatigue included restless leg syndrome (P = .006), diabetes mellitus (P = .045), fibromyalgia (P < 0.001), chronic fatigue syndrome (P = .006), and chronic kidney disease (P = .02). Current use of antidepressants (P<.001), antihistamines (P = .0276), antianxiety medications (P = .0357), and prescription pain medications (P<.001) were found to be associated with worsened fatigue. Nearly 25% of respondents scored > 2 on the Patient Health Questionnaire, indicating a high probability of depression. Higher Brief Fatigue Inventory score, Myeloproliferative Neoplasm Total Symptom Score, and individual symptom items were all associated with a higher likelihood of depressive symptoms (P<.0001). CONCLUSIONS: The management of fatigue should be multifactorial, with a comprehensive assessment and treatment plan to address all modifiable fatigue etiologies. Patients with MPNs likely have a higher prevalence of mood disturbances compared with the general population, suggesting the need to assess and intervene in this domain.
BACKGROUND:Patients with myeloproliferative neoplasms (MPNs) experience a high persistence, prevalence, and severity of fatigue. There is currently only limited information regarding factors that contribute to fatigue in patients with MPNs. METHODS: A 70-item, Internet-based survey regarding fatigue was developed by MPN investigators and patients/advocates and hosted by the Mayo Clinic Survey Research Center. RESULTS:Fatigue was found to be prevalent and severe among international survey respondents (1788 respondents). Higher body mass index (P<.001), current use of alcohol (P<.001), and current tobacco use (P = .0025) were found to be significantly associated with greater fatigue. Moderate/severe fatigue was present more frequently in those individuals who did not exercise compared with those who reported exercising at least once per week (P<.001). Medical comorbidities found to be significantly associated with greater fatigue included restless leg syndrome (P = .006), diabetes mellitus (P = .045), fibromyalgia (P < 0.001), chronic fatigue syndrome (P = .006), and chronic kidney disease (P = .02). Current use of antidepressants (P<.001), antihistamines (P = .0276), antianxiety medications (P = .0357), and prescription pain medications (P<.001) were found to be associated with worsened fatigue. Nearly 25% of respondents scored > 2 on the Patient Health Questionnaire, indicating a high probability of depression. Higher Brief Fatigue Inventory score, Myeloproliferative Neoplasm Total Symptom Score, and individual symptom items were all associated with a higher likelihood of depressive symptoms (P<.0001). CONCLUSIONS: The management of fatigue should be multifactorial, with a comprehensive assessment and treatment plan to address all modifiable fatigue etiologies. Patients with MPNs likely have a higher prevalence of mood disturbances compared with the general population, suggesting the need to assess and intervene in this domain.
Authors: Daniel C McFarland; Kelly M Shaffer; Heather Polizzi; John Mascarenhas; Marina Kremyanskaya; Jimmie Holland; Ronald Hoffman Journal: J Natl Compr Canc Netw Date: 2017-12 Impact factor: 11.908
Authors: Gina L Mazza; Katie L Kunze; Blake T Langlais; Heidi E Kosiorek; Todd A DeWees; Holly L Geyer; Robyn M Scherber; Ruben A Mesa; Amylou C Dueck Journal: Leuk Lymphoma Date: 2019-01-17